ImaginAb has inked an exclusive technology development partnership with fellow imaging agent developer Novotectid to develop antibody-based imaging agents to image CD4+ immune T cells.
For ImaginAb, the deal will broaden the potential scope of several of its biopharma collaborations, particularly for autoimmune diseases, ImaginAb CEO Christian Behrenbruch, PhD, said in a statement.
Novotectid CEO Michael Lutz, PhD, said the Leipzig, Germany-based company elected to partner with ImaginAb to improve its ability to manufacture and clinically deploy its technology, as well as to leverage key biopharma collaborations. Novotectid has demonstrated a viable clinical proof of concept, safety, and tolerability for imaging CD4+ cells with a monoclonal antibody fragment in arthritis patients, Lutz said.
The companies did not disclose the financial terms of their partnership.
